Skip to content
Sign in
Artwork for BackTable Urology
Health & FitnessMedicineEducation

BackTable Urology

BackTable Inc.

The BackTable Urology Podcast is a resource for practicing urologists to learn tips, techniques, and practical advice from their peers in the field. Listen here or on the streaming platform of your choice.

Play
Open in
  • 22 episodes
  • weekly
  • Avg 50 min
  • English

Episodes 22

NewestOldestLongest
All2Unplayed2In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • June 23 · 54 min

    Ep. 311 Career Diversification for Urologists Beyond the Clinic with Dr. Pat Keegan and Dr. Kelly Parsons

    What happens when urologists look beyond the clinic and take on leadership in the life sciences industry? In this episode of BackTable Urology, host Dr. Raj Pruthi talks with Dr. Kelly Parsons and Dr. Pat Keegan about their journeys from academic urology to executive roles in biotech and pharma. They discuss what motivated their transitions, how physician expertise adds value in industry, and the realities of life outside of traditional clinical practice. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction 05:36 - Choosing a Non-Clinical Path 11:07 - Reactions from Mentors and Peers 14:31 - What Feels Most Fulfilling 18:31 - A Typical Week in Biotech 26:04 - Working with Investors 31:21 - Additional Degrees and MBA Debate 35:31 - Is it Risky to Leave Clinical Practice? 44:13 - Networking and Next Steps 47:59 - Wrap Up --- More about this episode The conversation explores the day-to-day work of industry leaders, the impact of advanced degrees like MBAs, and the importance of networking for physicians considering a nonclinical path. Drs. Parsons and Keegan reflect on the challenges and rewards of leaving clinical medicine, the support and reactions from mentors and peers, and what they miss most about patient care. They also share practical advice for urologists and other specialists who are curious about new career opportunities beyond the exam room. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

  • June 18 · 43 min

    Ep. 310 Bladder Cancer Risk Stratification: Best Practices with Dr. Sunil Patel and Dr. Kristen Scarpato

    Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate and high-risk patients? In this episode of BackTable, Dr. Bogdana Schmidt interviews urologists Dr. Kristen Scarpato and Dr. Sunil Patel to explore the complexities of diagnosis and risk assessment in non–muscle invasive bladder cancer (NMIBC). They discuss the real-world challenges of pathology interpretation, risk-group assignment, evolving diagnostic tools, and the impact these factors have on treatment decisions and patient outcomes. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Introduction 01:02 - Risk Stratification 07:22 - Upstaging to High Risk 10:06 - Calculators and Patient Education 15:22 - Specific Tests Use Cases 18:50 - Conflicting Biomarker Results 21:36 - Adjunct Tests and Counseling 24:03 - Recurrence After Chemo Next Steps 27:01 - Escalation Deescalation Balance 32:48 - Future Research Priorities 35:43 - Biology Based Risk Stratification 38:03 - Clinical Pearls and Wrap Up --- More about this episode The conversation highlights the heterogeneity of intermediate-risk disease, the role and importance of expert pathology over-reads, and the need to accurately document the risk category for ongoing care. They discuss selective use of urinary and genomic assays and how these tests fit alongside cystoscopy and blue light endoscopy. Practical treatment approaches are reviewed, including when to use intravesical gemcitabine or BCG, managing care during BCG shortages, and balancing escalation versus de-escalation of therapy. Additional topics include strategies for long-term surveillance, upper tract imaging, rising rates of bladder cancer in younger patients, and why thorough TURBT and strong patient-provider communication remain central to optimal management. --- Resources The Memorial Study https://www.mskcc.org/cancer-care/clinical-trials/19-288 The BRIDGE Study https://www.nejm.org/doi/full/10.1056/NEJMoa1501035 --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Showing 21–22 of 22 episodes